This business information is not released now.

This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.

Cyfuse Biomedical K.K.
Medical care/Diagnosis/Medical equipment/Healthcare
Drug discovery support/Contract service
last update:2017/5/26

Delegates :
Takakiyo Kawano

Incorporated :
August  11 , 2010

Paid in Capital :
100 Million yen  

Employees :
23 人

Address :
University of Tokyo Entrepreneur Plaza 7-3-1 Hongo, Bunkyo-ku TOKYO

+81-3-4455-7872 / +81-3-6240-0034


Attachment :

Mission/Background :
Cyfuse is a regenerative medicine startup founded in 2010 to develop its proprietary technology to assemble living cells in three dimensions. The technology is based on the research results of Professor Koichi Nakayama of Saga University during his time at the Department of Orthopedic Surgery at Kyushu University. Cyfuse has been developing this technology until now with the support of the Japan Science and Technology Agency (JST) and the New Energy and Industrial Technology Development Organization (NEDO). In 2010, Cyfuse began working with Shibuya Kogyo Co., Ltd. to jointly develop a bio 3D printer called “Regenova” that automatically assembles cellular aggregates. Shipment of Regenova to Japanese universities began in 2013. Cyfuse’s main business activities include the sales of Regenova bio 3D printers, research and development of 3D tissue products, and subcontract manufacturing of 3D tissue products.

Technology & Business
The company’s technology uses a fine needle array to skewer cellular aggregates (0.5mm diameter), which are then stacked three dimensionally. Once the cellular aggregates are fused together, the needles are removed, resulting in elastic tissue based on the original cells and the collagen within. The Regenova bio 3D printer can automatically create a 3D cellular structure by inputting 3D data and cellular aggregate material. The resulting cellular structure spends several days or weeks maturing in a customized bioreactor, and comes to express its target strength and function. This technology can be used with various cell types, and is expected to bring breakthroughs in drug discovery research and regenerative medicine in a wide range of therapeutic areas. Cyfuse is involved in two on-going AMED projects. Phase I clinical research is on-going at Kyushu University hospital regarding OsteoChondral regeneration by implantation of 3D MSC constructs.

Products & Service
Products & Service Name
Bio 3D printer "Regenova"
The only commercially available scaffold-free bio 3D printer
Enter Chinese and European market. Find strategic partners for clinical development of the cellular applications.

SAN DIEGO, Feb. 8, 2016 -- Cell Applications, Inc. and Cyfuse Biomedical have announced that advanced tissue-engineering services are now available in North America using a new 3D bioprinter by Cyfuse.

VIRGINIA BEACH, Feb. 16, 2016 -- The LifeNet Health Institute of Regenerative Medicine is taking a step toward the future of biomedical science and tissue engineering with the installation of a robotic bioprinter at its primary research and development facility in Virginia Beach.

Hot news
Tokyo, February 27, 2015 Cyfuse announced that it has completed a 1.4 billion yen Series B funding round participated in by 12 investors, including venture capital funds and corporate investors.

Cyfuse’s presentation of 3D in-vitro Liver Project for drug screening was selected as a PRESS HIGHLIGHTs at “136th Annual Meeting of Pharmaceutical Society of Japan”, which will be held on 26th March 2016.

Alliance strategy
Cyfuse is looking for 1) collaboration partners (academia and business) to explore therapeutic applications using our 3D printing technology, 2) Licensees of 3D fabrication technology for commercial use.

This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.